News

Rationales of GcMAF as a therapeutic target for SARS-CoV-2

Rationales of GcMAF as a therapeutic target for SARS-CoV-2

*詳細は以下のPDFで紹介されております。英語の記事となりますが是非ご参照ください。

The fact that around 96% of patients recover from the infection despite there being no antiviral therapeutics that specifically target human coronaviruses suggests that the human immune system has mechanisms to combat SARS-CoV2. (英文 PDF)